Robert S. Brown, Brian J. McMahon, Anna S.F. Lok, John B. Wong, Ahmed T. Ahmed, Mohamed A. Mouchli, Zhen Wang, Larry J. Prokop, Mohammad Hassan Murad, Khaled Mohammed – 13 November 2015 – Perinatal or mother‐to‐child transmission (MTCT) of hepatitis B virus (HBV) remains the major risk factor for chronic HBV infection worldwide. In addition to hepatitis B immune globulin and vaccination, oral antiviral therapies in highly viremic mothers can further decrease MTCT of HBV.

Anna S.F. Lok, Brian J. McMahon, Robert S. Brown, John B. Wong, Ahmed T. Ahmed, Wigdan Farah, Jehad Almasri, Fares Alahdab, Khalid Benkhadra, Mohamed A. Mouchli, Siddharth Singh, Essa A. Mohamed, Abd Moain Abu Dabrh, Larry J. Prokop, Zhen Wang, Mohammad Hassan Murad, Khaled Mohammed – 13 November 2015 – Chronic hepatitis B viral (HBV) infection remains a significant global health problem. Evidence‐based guidelines are needed to help providers determine when treatment should be initiated, which medication is most appropriate, and when treatment can safely be stopped.

Maureen M. Jonas, Anna S.F. Lok, Brian J. McMahon, Robert S. Brown, John B. Wong, Ahmed T. Ahmed, Wigdan Farah, Mohamed A. Mouchli, Siddharth Singh, Larry J. Prokop, Mohammad Hassan Murad, Khaled Mohammed – 13 November 2015 – Most individuals with chronic hepatitis B viral (HBV) infection acquired the infection around the time of birth or during early childhood. We aimed to synthesize evidence regarding the effectiveness of antiviral therapy in the management of chronic HBV infection in children.

Vijay H. Shah, Greg J. Gores, Nick F. LaRusso – 13 November 2015

Maureen M. Jonas, Anna S.F. Lok, Brian J. McMahon, Robert S. Brown, John B. Wong, Ahmed T. Ahmed, Wigdan Farah, Mohamed A. Mouchli, Siddharth Singh, Larry J. Prokop, Mohammad Hassan Murad, Khaled Mohammed – 13 November 2015 – Most individuals with chronic hepatitis B viral (HBV) infection acquired the infection around the time of birth or during early childhood. We aimed to synthesize evidence regarding the effectiveness of antiviral therapy in the management of chronic HBV infection in children.

Anna S.F. Lok, Brian J. McMahon, Robert S. Brown, John B. Wong, Ahmed T. Ahmed, Wigdan Farah, Jehad Almasri, Fares Alahdab, Khalid Benkhadra, Mohamed A. Mouchli, Siddharth Singh, Essa A. Mohamed, Abd Moain Abu Dabrh, Larry J. Prokop, Zhen Wang, Mohammad Hassan Murad, Khaled Mohammed – 13 November 2015 – Chronic hepatitis B viral (HBV) infection remains a significant global health problem. Evidence‐based guidelines are needed to help providers determine when treatment should be initiated, which medication is most appropriate, and when treatment can safely be stopped.

Thamara Perera, Hynek Mergental, Barney Stephenson, Garrett R. Roll, Hentie Cilliers, Richard Liang, Roberta Angelico, Stefan Hubscher, Desley A. Neil, Gary Reynolds, John Isaac, David A. Adams, Simon Afford, Darius F. Mirza, Paolo Muiesan – 13 November 2015

Francis Y. Yao, Nicholas Fidelman – 11 November 2015 – Down‐staging of hepatocellular carcinoma prior to liver transplantation (LT) has generated a lot of interest in recent years and has been identified in two recent national conferences on hepatocellular carcinoma as one of the priorities for research. Down‐staging is defined as reduction in the tumor burden using local regional therapy specifically to meet acceptable criteria for LT.

Jeffrey Cui, Elhamy Heba, Carolyn Hernandez, William Haufe, Jonathan Hooker, Michael P. Andre, Mark A. Valasek, Hamed Aryafar, Claude B. Sirlin, Rohit Loomba – 11 November 2015 – Magnetic resonance elastography (MRE), an advanced magnetic resonance–based imaging technique, and acoustic radiation force impulse (ARFI), an ultrasound‐based imaging technique, are accurate for diagnosing nonalcoholic fatty liver disease (NAFLD) fibrosis. However, no head‐to‐head comparisons between MRE and ARFI for diagnosing NAFLD fibrosis have been performed.

Francis Y. Yao, Nicholas Fidelman – 11 November 2015 – Down‐staging of hepatocellular carcinoma prior to liver transplantation (LT) has generated a lot of interest in recent years and has been identified in two recent national conferences on hepatocellular carcinoma as one of the priorities for research. Down‐staging is defined as reduction in the tumor burden using local regional therapy specifically to meet acceptable criteria for LT.